Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06653348

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Mazandaran University of Medical Sciences (from the registry)
Registry
  • NCT NCT06653348
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06653348. Randomized; single masking; primary purpose prevention. Start 2024-04-01 (actual); primary completion 2026-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Acronym
DEDAPT-TICA
Intervention (Drug)
Ticagrelor 60 + Aspirin
Intervention (Drug)
Ticagrelor 90 + aspirin
Lead sponsor
Mazandaran University of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct06653348
Content hash
28450b9e9973ddc4ecd3c9e692c43b314466e17bb7bd90a7b295923e583cec07